Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI

Autor: Michael, Walsh, Claudette, Bethune, Andrew, Smyth, Jessica, Tyrwhitt, Shiangtung W, Jung, Rosie Z, Yu, Yanfeng, Wang, Richard S, Geary, Jeffrey, Weitz, Sanjay, Bhanot
Rok vydání: 2021
Zdroj: Kidney international reports. 7(2)
ISSN: 2468-0249
Popis: Patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) have an increased risk of thrombotic events and bleeding. Antisense reduction of factor XI (FXI) with IONIS-FXIThis multicenter study enrolled 49 patients receiving HD in 2 parts. First, 6 participants (pharmacokinetics [PK] cohort) received 1 open-label 300 mg dose of IONIS-FXIThe PK of IONIS-FXIIONIS-FXI
Databáze: OpenAIRE